Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | COMT | P21964 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076243 | 0.88 | KDM4E (0.40) | KDM4EEGLN1L3MBTL1HSP90AA1NPC1 | |
| SCHEMBL4065155 | 0.79 | KDM4E (0.55) | KDM4EEGLN1L3MBTL1NPC1RAB9A | |
| SCHEMBL3241312 | 0.78 | KDM4E (0.54) | KDM4EEGLN1L3MBTL1NPC1RAB9A | |
| SCHEMBL4062569 | 0.76 | KDM4E (0.52) | KDM4EEGLN1L3MBTL1HSP90AA1LMNA | |
| SCHEMBL13993803 | 0.76 | KDM4E (0.52) | KDM4EEGLN1L3MBTL1HSP90AA1NPC1 | |
| SCHEMBL4072643 | 0.76 | KDM4E (0.44) | KDM4EEGLN1L3MBTL1ALDH1A1PSMD14 | |
| SCHEMBL7258792 | 0.75 | KDM4E (0.51) | KDM4EEGLN1L3MBTL1ALDH1A1PSMD14 | |
| SCHEMBL3239918 | 0.75 | KDM4E (0.51) | KDM4EL3MBTL1HSP90AA1NPC1RAB9A | |
| SCHEMBL966397 | 0.75 | KDM4E (0.51) | KDM4EEGLN1L3MBTL1HSP90AA1NPC1 | |
| SCHEMBL4765621 | 0.74 | KDM4E (0.43) | KDM4EEGLN1L3MBTL1HSP90AA1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664046-B1 | AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7462721-B2 | Aza-quinolinol phosphonate integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20070185007-A1 | Aza-quinolinol phosphonate integrase inhibitor compounds | JIN HAOLUN | 2007-08-09 | — | — | US | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1664046-A1 | AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050137199-A1 | Inhibition of HiV integrase compounds | GILEAD SCIENCES, INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2005028478-A1 | AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137199-A1 | Inhibition of HiV integrase compounds | CDKL5, CDKL1, CDKL3 | KDM4E 354/4885EGLN1 3429/4885L3MBTL1 37/4885 |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | TYMP, PNP, PIKFYVE | KDM4E 1618/4885EGLN1 3167/4885L3MBTL1 495/4885 |
| US-20070185007-A1 | Aza-quinolinol phosphonate integrase inhibitor compounds | CDKL5, CDKL1, CDKL3 | KDM4E 303/4885EGLN1 3818/4885L3MBTL1 333/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | KDM4E 1618/4885EGLN1 3167/4885L3MBTL1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.